Related Articles
Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer
Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial
Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors